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Objective: Gold nanoparticles have attracted enormous interest as potential theranostic agents. However, little is
known about the long-term elimination and systemic toxicity of gold nanoparticles in the literature. Hollow gold
nanospheres (HAuNS) is a class of photothermal conducting agent that have shown promises in photoacoustic
imaging, photothermal ablation therapy, and drug delivery. It’s very necessary to make clear the biosafety of HAuNS
for its further application.
Methods: We investigated the cytotoxicity, complement activation, and platelet aggregation of polyethylene glycol
(PEG)-coated HAuNS (PEG-HAuNS, average diameter of 63 nm) in vitro and their pharmacokinetics, biodistribution,
organ elimination, hematology, clinical chemistry, acute toxicity, and chronic toxicity in mice.
Results: PEG-HAuNS did not induce detectable activation of the complement system and did not induce detectable
platelet aggregation. The blood half-life of PEG-HAuNS in mice was 8.19 ± 1.4 hr. The single effective dose of PEG-HAuNS
in photothermal ablation therapy was determined to be 12.5 mg/kg. PEG-HAuNS caused no adverse effects after 10 daily
intravenous injections over a 2-week period at a dose of 12.5 mg/kg per injection (accumulated dose: 125 mg/kg).
Quantitative analysis of the muscle, liver, spleen, and kidney revealed that the levels of Au decreased 45.2%, 28.6%,
41.7%, and 40.8%, respectively, from day 14 to day 90 after the first intravenous injection, indicating that PEG-HAuNS
was slowly cleared from these organs in mice.
Conclusion: Our data support the use of PEG-HAuNS as a promising photothermal conducting agent.
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Nanoparticles have great potential for biomedical appli-
cation, not only to deliver pharmaceutics but also to be
used as novel diagnostic and therapeutic agents [1,2].
The difference in the toxicity profiles of bulk materials
and their corresponding nanoparticles owing to the tiny
physical dimensions of nanoparticles has been widely
recognized [3,4]. For example, carbon black is nontoxic;
however, carbon nanotubes and fullerene are highly
toxic when inhaled into the lung [5,6]. Similarly, the en-
hanced toxicity of titanium oxide nanoparticles has been* Correspondence: cvpelt@comcast.net; cli@mdanderson.org
5Department of Veterinary Medicine and Surgery, The University of Texas MD
Anderson Cancer Center, Houston 77030, TX, USA
2Department of Cancer Systems Imaging, Unit 59, The University of Texas
MD Anderson Cancer Center, Houston, TX 77030, USA
Full list of author information is available at the end of the article
© 2014 You et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.reported [7,8], and titanium oxide nanoparticles have
been shown to induce oxidative stress in bacteria [9].
Gold nanoparticles (AuNPs) show several features that
make them well suited for biomedical applications, in-
cluding straightforward synthesis, stability, and the abil-
ity to selectively incorporate recognition molecules such
as peptides or proteins [10]. AuNPs have been used as
Raman sensors [11], photocatalysts [12], photoelectro-
chemical materials [13], photothermal conducting agents
[14], biosensors [15], and carriers for the delivery of
drugs and genes [16-18]. Although AuNPs are thought
to be nontoxic [19-21], there are reports that document
their toxicity, which has been shown to depend on the
physical dimensions, surface chemistry, and shape of the
AuNPs [22-26].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of AuNPs composed of a thin Au shell with a hollow in-
terior. Unlike solid AuNPs, HAuNS have plasmon ab-
sorption in the near-infrared (NIR) region and display
strong photothermal conducting properties suitable for
photothermal ablation therapy. HAuNS’ unique combin-
ation of small size (30–50 nm in diameter) and a strong,
tunable absorption band (520–950 nm) suggests that
HAuNS are a promising mediator for a variety of bio-
medical applications, including imaging and cancer ther-
apy [27-30]. A few studies have explored the potential
utility of HAuNS as a novel delivery vehicle to shuttle
biomolecules [31,32] or to trigger drug release under
NIR light irradiation [33-35]. To date, there has been no
detailed study on the toxicity of HAuNS. Herein, we car-
ried out a biosafety evaluation of polyethylene glycol
(PEG, molecular weight of 5000)-coated HAuNS (PEG-
HAuNS), including in vitro blood compatibility and in vivo
acute and chronic toxicity assessment. We determined the
effective therapeutic dose in xenograft models of human
ovarian cancer and used the data to guide dose selection
for systemic toxicity study.
Results and discussion
Synthesis and characterization of HAuNS and PEG-HAuNS
HAuNS was readily coated with methoxy-PEG-sulfhydryl
(molecular weight, 5,000). The absorption spectra showed
that the plasma resonance peak for PEG-HAuNS was
tuned to the NIR region (~800 nm) (Figure 1A). The
homogeneity of HAuNS is demonstrated in Figures 1B
and C, which show representative scanning electronA
C
Figure 1 Characterization of HAuNS. A: Absorption spectra of HAuNS. B
high-resolution TEM images of HAuNS.micrograph and low-resolution TEM images of HAuNS.
The narrow size distribution of the HAuNS resulted
from the narrow size distribution of the cobalt seed
nanoparticles from which the HAuNS were grown. The
high-resolution TEM of an individual HAuNS, shown
in Figure 1D, illustrates the thin Au shell with hollow
interior. TEM reviewed an average size of 43.1 ± 5.4 nm
(Figure 1). Dynamic light scattering revealed an average
HAuNS diameter of 43.6 nm, and average polydisper-
sity of 0.006. PEGylation led to a significant increase in
the size of PEG-HAuNS, which had an average diam-
eter of 62.7 nm and polydispersity of 0.068. However,
compared with HAuNS, PEG-HAuNS had significantly
increased colloidal stability: no aggregation was ob-
served when PEG-HAuNS were stored in water at room
temperature over a period of 6 months. PEG modification
did not affect the extinction spectrum of HAuNS. The
physicochemical properties of HAuNS and PEG-HAuNS
are summarized in Table 1.
Cytotoxicity
The cytotoxicity of PEG-HAuNS against both LLC-PK1
and HepG2 cells increased with increased incubation time
(Additional file 1: Figure S1). PEG-HAuNS was more
toxic to kidney cells than to liver cells (HepG2): the IC50
values of PEG-HAuNS after 48 h of incubation in LLC-
PK1 and HepG2 cells were 0.22 mg/mL and >1 mg/mL,
respectively.
On the basis of cytotoxicity assay, gold nanoparticles
have been found to be “non-toxic” or “toxic”, depending
on the physicochemical characteristics (surface charge,D
B
: Scanning electron micrograph images of HAuNS. C and D: Low- and
Table 1 Physicochemical properties of HAuNS and
PEG-HAuNS
HAuNS PEG-HAuNS
Concentration (mg/mL) 2.5 × 10−3 2.5 × 10−3
Concentration (particles/mL) 6.25 × 109 6.25 × 109
Mean diametera (nm) 43.6 ± 0.4 62.7 ± 0.7
Polydispersitya 0.006 ± 0.001 0.068 ± 0.005
Zeta potential (mA) −23 ± 0.8 −15 ± 0.6
Plasma resonance peak (nm) 802 801
Optical densityb 0.112 0.110
aData are presented as mean ± standard deviation (n = 3), measured by dynamic
light scattering. bOptical density measured at 800 nm.
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direct comparison of our results with those reported in
the literature would not be possible because of differ-
ences in nanoparticle characteristics and cell lines used
in these studies. Nevertheless, Patra el al. [36] found
that gold nanoparticles of 33 nm in diameter, which
was only slightly smaller than our HAuNS, were not
toxic to Hep2G and BHK21 (baby hamster kidney)
cells. In our cytotoxicity study, concentrations of
0.22 mg/mL and > 1 mg/mL for LLC-PK1 and Hep2G
cells respectively were quite high. At such concentra-
tions, absorption at 495 nm by residual nanoparticles
may affect MTT assay results as suggested by Alkilany
et al. [26]. Because we have observed that the decreaseC3 split 
product
PC     NC      PEG-HAuNS
A
Figure 2 In vitro complement activation and platelet aggregation ass
nanoparticles did not result in the detectable activation of a complement s
B: Platelet aggregation in the presence of PEG-HAuNS. PEG-HAUNS under tes
under tested concentrations did not interfere with collagen-induced plateletin optical density as a function of particle dose depended
on incubation time, suggesting that the effect of residual
nanoparticles on the MTTassay was not significant.
Complement activation and platelet aggregation
To examine potential effects of PEG-HAuNS on the com-
plement activation cascade, we assessed the degree of com-
plement activation in an in vitro assay in human plasma
aliquots pretreated with nanoparticles. PEG-HAuNS did
not induce detectable activation of the complement system
in a C3-specific qualitative assay (Figure 2A). Furthermore,
PEG-HAuNS under the tested concentrations did not in-
duce any detectable platelet aggregation (Figure 2B) and
did not interfere with collagen-induced platelet aggregation
(Figure 2C).
Pharmacokinetics and biodistribution
Figure 3A shows the mean blood level profile of 64Cu-
labeled PEG-HAuNS. Terminal biological half-life, ap-
parent volume of distribution, total body clearance,
mean residence time, and total area under the blood
concentration were 8.19 ± 1.4 hr, 2.78 ± 0.63 mL, 0.235 ±
0.03 mL/hr, 12.3 ± 2.2 hr, and 434 ± 61%ID · hr/mL,
respectively. Figure 3B shows the biodistribution of
PEG-HAuNS in Hey tumor-bearing mice at 24 h after
intravenous injection. Most nanoparticles were taken up by
the liver (11.8 ± 1.95%ID/g) and spleen (8.51 ± 1.67%ID/g).
Because blood was not perfused prior to measurements inPC    0.008    0.04     0.2      1.0
PEG-HAuNS (mg/mL)




ays. A: Complement activation assay of PEG-HAuNS (1 mg/mL). The
ystem. PC, positive control (cobra venom), NC, negative control (PBS).
ted concentrations did not induce platelet aggregation. C: PEG-HAUNS
aggregation. PC, positive control (collagen).
AB
Figure 3 Pharmacokinetics and biodistribution of PEG-HAuNS.
A: Blood level profiles of 64Cu-labeled PEG-HAuNS. The data are
expressed as a percentage of the injected dose (5.0 mL/kg of 50 OD
PEG-HAuNS, 1.25 mg/mL) per gram of blood (%ID/g) and are presented
as mean ± standard deviation (n = 8). B: Biodistribution of 64Cu-labeled
PEG-HAuNS in mice at 24 h after intravenous injection (n = 6).
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be overestimated owing to the contribution of PEG-
HAuNS in the blood in these organs. A significant
amount of PEG-HAuNS also accumulated in the tu-
mors (3.22 ± 0.86%ID/g), which could be attributed to
the enhanced permeability and retention effect.
Tissue distribution of PEGylated gold nanoparticles
have been reported by several groups. A direct compari-
son of our results with those reported in the literature is
difficult because particle characteristics (size, surface
chemistry, charge etc.) of these gold nanoparticles are
very different. Lankveld et al. [37] found that spleen was
the major organ of particle deposition in rats for PEGy-
lated gold nanorods (55.3 × 18.5 nm). Similar finding was
reported by Akiyama et al. [38] using PEGylated nanorods
of 55 × 9 nm in average size in mice. Interestingly, a PEGy-
lated gold nanorod preparation with slightly different size(65 × 11 nm) showed mostly liver uptake and minimal
spleen uptake 24 h after intravenous injection in mice
[39]. We have found a size-depend distribution pattern for
spherical gold nanoparticles coated with PEG. Thus,
PEGylated gold nanoparticles of smaller size (20-nm in
diameter) had longer blood half-life and lower uptake in
the liver and spleen than those of larger size (80-nm in
diameter) [40]. In agreement with the current findings,
PEGylated gold nanoparticles were largely distributed to
the liver and the spleen [40].
Antitumor activity
To facilitate selection of a more realistic dosing schedule
for assessment of toxicity of PEG-HAuNS, we first de-
termined the effective dose of PEG-HAuNS in NIR
laser-induced photothermal ablation therapy in a human
ovarian tumor model (Figure 4). Results from Hey
tumor-bearing nude mice showed a dose–response to
PEG-HAuNS at a laser output power of 2.5 W/cm2 for
3 min of continuous illumination. At a single dose of
5.0 mL/kg of 100 OD (12.5 mg/kg), PEG-HAuNS dis-
played the greatest antitumor activity (Figure 4A and B).
All of the tumors in this group shrank to small lumps,
which were barely palpable (Figure 4C). Average body
weight of the mice in the 50-OD and 100-OD dosing
groups decreased after NIR laser illumination, with about
5% body weight loss on day 4 after the illumination. No
change in body weight for the mice in both the saline and
25-OD dosing groups was observed during the same
period (Figure 4D). The body weight of all treated groups
started to recover 4 days after laser illumination.
Additional file 1: Figure S2 shows the A2780 tumor-
growth curves after intravenous injection of saline or PEG-
HAuNS (single dose, 5.0 mL/kg of 50 OD, 6.25 mg/kg),
followed by NIR laser treatment (2.5 W/cm2 for 3 min) at
24 h after injection. PEG-HAuNS followed by NIR laser
treatment significantly inhibited the growth of the tu-
mors. The average tumor weight in this group on day
21 was 0.1 ± 0.02 g, which was significantly smaller than
that of the saline and laser-treated control groups (2.0 ±
0.4 g) (p < 0.001). Thus, a single dose of PEG-HAuNS
ranging from 6.25 mg/kg to 12.5 mg/kg were effective in
mediating photothermal ablation therapy.
Acute and chronic toxicity
The available literature on in vitro and in vivo toxicity of
AuNPs showed contradicting findings, primarily because
in vivo behaviors of AuNPs are dependent on their physi-
cochemical characteristics [26]. Little is known about
AuNPs’ elimination from major organs and their long-
term biosafety after intravenous injection [26]. In this con-
text, there is a real need to investigate the in vivo toxicity
of gold-based nanoparticles intended for therapeutic use,
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Figure 4 Antitumor activity of PEG-HAuNS against Hey tumors in nude mice. A: Hey tumor growth curves in mice treated with saline (n = 7),
and PEG-HAuNS at doses ranging from 5 mL/kg of 25 OD (n = 7, 3.125 mg/kg), 50 OD (n = 8, 6.25 mg/kg), and 100 OD (n = 8, 12.5 mg/kg). All tumors
received NIR laser illumination from the tumor’s surface (2.5 W/cm2, for 3 min) at 24 h after a single dose nanoparticle injection. B: Average weight of
tumors in saline- and PEG-HAuNS-treated groups on day 10 after NIR laser illumination. C: Photographs of excised tumors on day 10 after NIR
laser illumination. D: Percentage change in mean body weight.
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PEG-HAuNS was conducted at an intravenous dose of
12.5 mg/kg per injection, for a total of 10 injections ad-
ministered over a 2 week period. No clinical signs were
observed during the course of the study, and all animals
survived until their scheduled termination. No toxico-
logically important alterations in body weights and relative
organ weights were observed at either time point (day 14Table 2 Group means for both sacrifice dates and both sexes
Parameter* Creatinine BUN AST
Unit mg/dL mg/dL mg/dL
14 days (Female) Saline <0.20 16.1 443
PEG-HAuNS <0.20 14.3 515
90 days (Female) Saline <0.20 16.9 273
PEG-HAuNS <0.20 16.4 406
14 days (Male) Saline <0.20 18 112
PEG-HAuNS 0.2 19.8 322
90 days (Male) Saline 0.22 20.3 152
PEG-HAuNS 0.27 17.6 591
Reference ranges Males 0-0.4 23-38 0-541
Females 0-0.4 19-33 0-671
*BUN - blood urea nitrogen, AST - aspartate aminotransferase, ALT - alanine aminotrand day 90 after start of treatment) (See Additional file 1:
Tables S1 and S2 for specific group means and calculated
percent of control).
Hematology
A complete blood count and clinical chemistry parameters
were performed on the cardiac blood collected at the time
of necropsy for both 14-day and 90-day time points. Table 2for clinical chemistry
ALT ALK PHOS T. Protein Albumin Globulin
IU/L IU/L IU/L g/dL g/dL
259 128 4.91 3.63 1.29
316 136 5.18 3.59 1.58
130 92 5.8 3.61 2.19
202 84 5.88 3.75 2.13
69 123 5.63 3.55 2.07
256 123 5.52 3.33 2.19
109 137 6.62 3.83 2.79
395 204 6.62 3.76 2.85
0-561 110-219 5.1-6.2 2.5-3.2 2.5-3.0
0-596 113-223 5.3-6.3 2.8-3.5 2.4-2.9
ansferase, ALK PHOS - alkaline phosphatase, T. protein - total protein.
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means for each group and the laboratory reference range
for 6- to 8-week-old CD-1 mice using the same instru-
ments used in this study. Differences in the mean values of
the PEG-HAuNS-treated groups are highlighted if there
were alterations from their respective concurrent control
group.
The only alterations in hematology (using concurrent
controls) occurred in females at 14 days. The total white
blood cell, absolute lymphocyte, and eosinophil counts
were slightly elevated but returned to normal by the 90-
day time point. These alterations were minimal and not
considered toxicologically important.
Clinical chemistry
The chemistry parameters evaluated were creatinine, blood
urea nitrogen, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase, total pro-
tein, albumin, and globulin.
The AST and ALT group means were increased in both
sexes at both day 14 and day 90, compared to their re-
spective controls. However, none of the groups, except the
males at the 90-day treatment time point, had an increase
above the reference range of the laboratory. Examination
of the individual animal data for these 2 parameters indi-
cated that mice in all the groups had samples with severely
hemolyzed sera that can falsely elevate both AST and
ALT. When the values for AST and ALT from animals
with severe hemolysis were eliminated from computation
of the group means, no increase above the reference range
for this laboratory was observed. On the basis of this ana-
lysis, this alteration in these 2 parameters appeared spuri-
ous, and related to sample quality, i.e., hemolysis. This
interpretation was supported by normal values for the
other clinical chemistry parameters measured to evaluate
the liver, i.e., total protein, albumin, and globulin levels.
This interpretation was also supported by the relative
organ weight data for the liver. Correlation with the histo-
pathology data showed very minimal focal necrosis and
minimal deposit of pigment in occasional hepatocytes that
could potentially increase both ALT and AST.
Gross pathology
PEG-HAuNS-related gross pathological findings observed
in the PEG-HAuNS-treated group on day 14 were limited
to liver lesions. This lesion was recorded as a discoloration
of the liver in all test animals from both sexes. This discol-
oration correlates with pigment observed in the Kupffer
cells of the liver on microscopic examination. No gross le-
sions were observed in any of the animals at day 90.
Microscopic pathology
Summary incidences and average group grades for all
microscopic observations at both day 14 and day 90were presented in Additional file 1: Tables S4. The major
microscopic observation in the PEG-HAuNS-treated
groups was deposition of a brown-black pigment in the
liver, spleen, lungs, heart, adrenal cortex, and injection
site. The largest amounts of pigment were observed in
the liver and spleen. All treated mice had deposition of
pigment in the liver (24/24) and 16/24 treated mice had
pigment deposited in the spleen. Pigment was more
prevalent at 14 days and had diminished by 90 days in
these 2 organs. The incidence of this pigment in the
other organs was as follows: lung (2/24), heart (7/24),
adrenal cortex (3/24), and injection site at the tail vein
(3/24). It was minimal in quantity, frequently occurred in
perivascular areas in these organs, and generally was not
associated with inflammatory or degenerative changes. It
is not clear why PEG-HAuNS stayed at perivascular areas.
One possible explanation is that these nanoparticles came
from blood during tissue processing because blood was
not perfused at the time of euthanization and tissue har-
vesting. Another possibility is that some of the nanoparti-
cles were able to penetrate endothelial lining and trapped
in the perivascular area. Further studies are needed to
clarify this interesting observation.
The major target organs were considered the liver and
spleen, and the monocytic-macrophage system was the
primary target.
Liver In both female and male mice, a dark, brown-
black pigment was observed, primarily in the macro-
phages (Kupffer cells) of the liver and occasionally in a
few hepatocytes. This pigment was present in nearly all
Kupffer cells at the 14-day time point in females and
males, but there was a decrease in the number of Kupffer
cells affected and a slight decrease in the quantity (lesion
grades) of the pigment at the 90-day time point in both fe-
males and males (Figure 5A). Special stains (Perl’s iron,
Schmorl’s stain for lipofuscin, Periodic Acid-Schiff [PAS],
and acid-fast) (Figure 5B) were done to characterize this
pigment. The Schmorl’s stain was positive in the liver and
spleen, but the other stains to confirm lipofuscin (PAS,
acid-fast) were negative, indicating the pigment was not
lipofuscin. Samples of formalin-fixed liver were submitted
for transmission electron microscopic study (TEM) and
confirmed that the pigment observed in the Kupffer cells
and some hepatocytes was electron-dense nanospheres
comparable to the injected PEG-HAuNS (Figure 6A).
To further confirm liver uptake of PEG-HAuNS, sam-
ples of liver were submitted for Au quantification using
neutron activation analysis (control and treated at both
time points). Au was only detected in the treated sam-
ples. Although there was a general trend of decreasing
concentration from day-14 to day-90 for muscle, liver,
spleen, and kidney in both male (n = 3) and female mice






Figure 5 Liver pigment. A: Arrows point to pigment in both 14-day and 90-day liver tissues. The 14-day tissue has more Kupffer cells filled with
pigment. The 90-day tissue has pigment but fewer Kupffer cells with pigment. B: Section of liver pigment stained with PAS, Perl’s iron, Schmorl’s,
and acid fast. Schmorl's stain has some of the slightly blue reaction for lipofuscin, but the other lipofuscin stains (PAS, acid fast) do not have the
characteristic color for lipofuscin. The Perl’s iron stain is negative for iron. Magnification: ×400.
You et al. Particle and Fibre Toxicology 2014, 11:26 Page 7 of 14
http://www.particleandfibretoxicology.com/content/11/1/26significant with the exception of spleen in female mice
(p = 0.05). However, when data from both male and female
mice are combined (n = 6), significant differences in tissue
concentration of Au for all organs analyzed (muscle, liver,
spleen, and kidney, with p values of 0.006, 0.027, 0.011,
and 0.015, respectively) were demonstrated (Figure 6C).
Thus, the levels of Au in the muscle, liver, spleen, and kid-
ney decreased 45.2%, 28.6%, 41.7%, and 40.8%, respect-
ively, from day 14 to day 90 after the first intravenous
injection (Table 3). These data suggest that PEG-HAuNS
could be cleared from the body, albeit at a very slow rate.
Both inflammation and necrosis were minimal in the
livers. Inflammation occurred in both control and
treated animals of both sexes at both time points, but
there was a slightly higher incidence and minimally in-
creased severity in the treated animals. At day 90, the in-
cidence and severity decreased slightly in females but
increased slightly in males. The severity grade was slight
and not considered adverse. Focal necrosis was observed
in female mice only at the 90-day time point, with an in-
cidence of 2 (out of 6 mice) and an average grade of 1.
In male mice, focal necrosis was observed at the 14-day
time point, with an incidence of 3 of 6 and a grade of 1,
but not at the 90-day time point. Since an incidence of
only 1 was observed in the male controls at day 14, there
was a very slight increase in focal necrosis in both fe-
males and males; however, the time of occurrence did
not correlate between the sexes. Thus, this is a minimal
increase over controls and not considered adverse.In summary, the major hepatic lesion was a deposition
of pigment in the macrophages of the liver (Kupffer
cells). The pigment was identified as a deposition of the
Au nanospheres by both TEM and quantitative analysis
of selected formalin-fixed samples of liver from this
study (Figure 6). Comparison of pigment in histopath-
ology samples between groups and quantitative analysis
for Au indicate that the deposited pigment was greatest
at the 14-day time point and was decreasing at the 90-
day time point, indicating slow clearance at 90 days.
Minimal hepatic lesions of inflammation and necrosis
were observed, but the incidence and severity were minimal
in both sexes and not considered adverse. The increase and
continued presence of mononuclear inflammation in both
sexes suggest these cells may be recruited macrophages for
the removal of pigment, a normal biologic response that
does not have adverse effects.
Spleen A dark brown-black pigment consistent with the
pigment observed in the liver was observed in the mac-
rophages of the spleen in the treated animals at both
time points. At 14 days the pigment deposition was
small and diffusely throughout the spleen. At 90 days,
the pigment was larger but fewer aggregates distributed
focally and randomly throughout the spleen (Additional
file 1: Figure S3). Based on the histopathologic analysis
and the Au quantification (Figure 6B), this pigment was
interpreted to be the injected PEG-HAuNS. Its presence
in the macrophages of the spleen is considered a normal



































Figure 6 Clearance of Au nanoparticles from mice. A: Representative transmission electron microscopy images of liver tissues from PEG-HAuNS-
and saline-treated mice at the 14-day time point. Au nanoparticles and pigment were found only in the PEG-HAuNS-treated mice, indicating that the
pigment in the macrophages of the liver (Kupffer cells) was attributed to PEG-HAuNS. B: Au concentration (ppm) in various dried tissue samples from
male (n = 3) and female (n = 3) mice at day 14 and day 90 after the first injection of PEG-HAuNS. The p values (two tailed student’s t-test) are provided
in the graphs. C: Tissue concentration of Au expressed as percentage of injected dose per gram drug tissue (%ID/g) obtained from both female and
male mice (n = 6). ** p < 0.01; * p < 0.05.
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adverse. An increase in follicular lymphoid hyperplasia
and extramedullary hematopoiesis was observed in PEG-
HAuNS-treated animals compared to the respective
controls, but the incidence and severity was minimal,
considered a normal biologic response to injection of
foreign material, and not adverse.
Lung Several types of inflammation were observed in
the lungs; these inflammatory lesions included mono-
nuclear (histiocytic) cells and granuloma formation.
These lesions were more prevalent in the treated animals
than in the controls. In the treated animals, a darkTable 3 Percentage decrease in gold concentration in
various organs for male and female mice from day 14 to
day 90
Muscle Liver Spleen Kidney
Males (n = 3) 44.6 25.2 26.2 38.8
Females (n = 3) 45.7 30.8 58.6 41.8
Males & females (n = 6) 45.2 28.6 41.7 40.8brown-black pigment was found in a few of the inflam-
matory lesions (Figure 7A). In the female mice, the inci-
dence of the lesions was higher at the 14-day time point
when considering all lesions and decreased at the 90-day
time point, indicating recovery. In the male mice, the le-
sions were fewer and less severe but persisted to the 90-
day time point. Special stains (PAS, Perl’s iron, Schmorl’s
stain for lipofuscin, acid fast) did not identify any foreign
material in the granulomas. All lesions except 1 were
grade 1, indicating minimal involvement. On the basis of
this minimal involvement, the lesions were not consid-
ered adverse. While some of these lesions may or may
not be related to treatment, they are minimal severity,
and low incidence and not considered to have any sig-
nificant impact on the health of the animals with them.
Heart Murine cardiomyopathy occurs in mice and the
morphologic changes include myocyte degeneration/ne-
crosis, an increase in the amount of interstitial fibrous
connective tissue, and in some cases a minimal to mild
infiltrate of mononuclear inflammatory cells. These age-
related cardiomyopathy have been reported in different
AB
Figure 7 Pigment in lung and heart. A: The image on the left is from a 14-day-PEG-HAuNS-treated animal with peribronchiolar inflammation.
Arrow points to pigment. B: Arrow points to pigment in lung tissue from a 90-day-PEG-HAuNS-treated animal. Magnification: ×400.
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tive lesions typical of spontaneous cardiomyopathy (mono-
nuclear inflammation, myocyte degeneration, fibrosis) were
observed in both the treated and control animals. However
in the treated mice, these lesions were sometimes associ-
ated with very small deposits of dark brown pigment simi-
lar to that observed in other organs. This pigment was
observed in 7/24 treated animals (Figure 7B) but in none of
the 3/24 controls that had cardiac lesions. These lesions
would have been classified as spontaneous cardiomyopathy
if the pigment had not been present. Since pigment is not
typical of cardiomyopathy, these lesions were tabulated in-
dividually and not included under the cardiomyopathy that
was used in the controls. Special stains did not identify the
pigment, and all heart tissue was used in the histopatho-
logic analysis. The pigment deposit in each case was min-
imal and generally a single observation in the sections of
the heart examined. What cannot be explained is whether
the pigment deposition was incidental to the lesions or
whether its presence contributed to the development of the
lesions. On the basis of the number and size of the lesions,
these lesions were not considered adverse. They may or
may not be related to the compound, but are not of the se-
verity or frequency to impact the health of the animal.
Adrenal The adrenal gland in only the female mice had
an increase in vacuolation of the cortex and pigment de-
position in the cortex at the 14-day time point in thetreated animals but not in their respective controls. By
90 days, the treated females had less vacuolation in the
cortex than their respective controls, but the pigment
deposition remained. Vacuolation of the adrenal cortex
in the female mice occur as a result of the spontaneous
regression of the X-zone of the cortex and its replace-
ment with fat that can undergo lipogenesis (formation of
lipid pigments such as lipofuscin). Special stains for lipo-
fuscin were negative on the pigment in the adrenal cor-
tex. Since the morphology of the pigment was similar to
that observed in the heart and liver, it was presumed to
be HAuNS. As observed in the heart, the pigment was
minimal at best and usually only a single observation in
the tissue section. Its association with a normal spontan-
eous process (regression of the X-zone) may be inciden-
tal. On the basis of the size of the deposits, this lesion
was not considered adverse.
Injection site Deposition of a dark brown pigment simi-
lar to that observed in other tissues and identified as
HAuNS occurred in the perivascular area and the wall of
vessels at the injection site at the tail vein in 3/24 treated
animals — 2 in the 14-day group and 1 at 90 days. On the
basis of the size of the lesions and frequency of tissue re-
action to the pigment, it was not considered adverse.
Other organs Microscopic lesions were observed in
other organs: kidney, brain, eyes (retina), spinal cord,
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ated lymph nodes and thyroid. These observations oc-
curred in both the control and treated animals and did
not have an increased incidence in treated animals com-
pared to controls. These lesions are common observations
in this strain of laboratory mouse and are considered inci-
dental and spontaneous in this study.
Conclusion
In this work, we investigated the cytotoxicity, blood com-
patibility, pharmacokinetics, biodistribution, and systemic
toxicity of PEG-HAuNS. In vitro, PEG-HAuNS did not in-
duce detectable complement activation and platelet aggre-
gation. Under the conditions of this study and on the
basis of clinical signs, survivability, clinical pathology, and
total body and relative organ weights and pathology, the
administration of PEG-HAuNS was not considered ad-
verse in female or male mice at an accumulated injection
dose of 125 mg/kg, which was 10-fold higher than the ef-
fective therapeutic dose. Pathologic and quantitative ana-
lysis for Au in formalin-fixed tissues indicated that the
levels of deposited HAuNS were decreased at 90 days, but
HAuNS was not completely eliminated. The primary test-
substance-related microscopic observation in this study
was the deposition of pigment, primarily in the macro-
phages of the liver and spleen that was identified as
HAuNS based on TEM and Au quantification. It is inter-
esting to note that the increase and continued presence of
mononuclear inflammation in the liver suggest these cells
may be recruited macrophages for the removal of pig-
ment, a normal biologic response that does not have ad-
verse effects. Minute deposits of pigment (assumed to be
HAuNS) were observed in the lung, heart, and adrenal
cortex (only in females) and at the injection site. Import-
antly, quantitative analysis for Au in the liver, spleen, and
kidney revealed that the levels of deposited PEG-HAuNS
gradually decreased from day 14 to day 90 after the first
injection, indicating that PEG-HAuNS was gradually
cleared from the body, albeit slowly. Completely eliminat-
ing Au from the body may take a much longer time.
Taken together, our data support the use of PEG-HAuNS
as a potential photothermal conducting agent.
Methods
Reagents
Methoxy-PEG-sulfhydryl (molecular weight, 5,000) was pur-
chased from Nektar (San Francisco, CA). (3-(4,5-Dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and
4,6-diamidino-2-phenylindole (DAPI) were purchased from
Sigma-Aldrich (St. Louis, MO). Trisodium citrate dehydrate
(>99%), cobalt chloride hexahydrate (99.99%), sodium boro-
hydride (99%), and chloroauric acid trihydrate (American
Chemical Society reagent grade) were purchased from
Fisher Scientific (Pittsburgh, PA) and were used as received.64CuCl2 radionuclide was obtained from Washington
University (St. Louis, MO).
Cell culture
Hey (human ovarian carcinoma) cells were purchased
from the American Type Culture Collection (Manassas,
VA). The Hey cells were maintained at 37°C in a humidi-
fied atmosphere containing 5% CO2 in Dulbecco’s modi-
fied Eagle’s medium (DEME) and 10% fetal bovine serum
(FBS, Life Technologies, Inc., Grand Island, NY). A2780
human ovarian carcinoma cells were kindly provided by
Dr. Stephen J. Williams (Fox Chase Cancer Center,
Philadelphia, PA) and maintained at 37°C in RPMI-1640
medium containing 10% FBS and insulin (0.25 units/mL).
LLC-PK1, an epithelial porcine kidney cell line with prox-
imal tubule properties, was obtained from the American
Type Culture Collection and was grown in DEME (1.0 g/L
glucose) supplemented with 10% FBS, 1% glutamine,
25 mmol/L (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) buffer, and antibiotics. Cells were divided twice a
week to ensure exponential growth and were cultured for
no more than 10 passages after thawing them from stock.
The human hepatocellular liver carcinoma cell line HepG2
(American Type Culture Collection) was cultured in DENE
with 10% FBS and antibiotics.
Synthesis and characterization of HAuNS and PEG-HAuNS
HAuNS were synthesized according to a previously re-
ported method [34]. Briefly, cobalt nanoparticles were
first synthesized by deoxygenating deionized water con-
taining 4.5 mL of 1-mol/L sodium borohydride, 2.8 mL
of 0.1-mol/L sodium citrate, and 1.0 mL of 0.4-mol/L
cobalt chloride. After chloroauric acid was added to the
solution containing the cobalt nanoparticles, the cobalt
immediately reduced the Au ions onto the surface of the
cobalt nanoparticles, while at the same time it was oxi-
dized to cobalt oxide. Any remaining cobalt core was
further oxidized by air, resulting in the final product,
HAuNS. The size of the HAuNS was determined using
dynamic light scattering on a Brookhaven 90 plus par-
ticle size analyzer (Holtsville, NY). Ultraviolet–visible
spectroscopy was recorded on a Beckman Coulter DU-
800 ultraviolet–visible spectrometer (Fullerton, CA). The
morphology of the HAuNS was examined using a JEM
1010 transmission electron microscope (JEOL USA, Inc.,
Peabody, MA). For the preparation of PEG-HAuNS,
briefly, 2 mL of HAuNS (100 optical density [OD]) were
added to argon-purged aqueous solution containing PEG
sulfhydryl (3 μmol). The reaction was allowed to proceed
overnight at room temperature. For purification, the re-
action mixture was centrifuged at 10,000 rpm for
15 min, and the resulting pellet was resuspended in de-
ionized water. The process was repeated twice to remove
any unattached PEG molecules.
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For conjugation of the radiometal chelator to PEG-
HAuNS, 1,4,7,10-tetraazacyclododecane -N, N', N'', N'''-
tetraacetic acid thioctamide (DOTA-TA, 1.0 mg/mL;
20 μL) was mixed with 1.0 mL of aqueous solution of
HAuNS (160 OD/mL) for 6 h at room temperature.
Unreacted DOTA-TA was removed by centrifugation at
10,000 rpm for 10 min. Then DOTA-conjugated HAuNS
was further reacted with PEG sulfhydryl to obtain
DOTA-conjugated PEG-HAuNS. Conjugating PEG to
HAuNS first followed by introduction of DOTA was
proven to be less efficient perhaps because the steric
barrier formed by PEG chains could prevent DOTA-TA
from approaching the surface of HAuNS. For radiolabel-
ing with 64Cu, aliquots of DOTA-conjugated PEG-
HAuNS (160 OD/mL) in 0.1-M sodium acetate solution
(pH 5.4) were mixed with an aqueous solution of
64CuCl2 (10 mCi) for 1 h. The radiolabeled nanoparticles
were then purified by centrifugation at 10,000 rpm for
10 min and washed 3 times with phosphate-buffered
saline. The nanoparticles were resuspended in phosphate-
buffered saline. The radiolabeling efficiency and the stabil-
ity of labeled nanoparticles were analyzed using instant
thin-layer chromatography. The paper strips were de-
veloped with phosphate-buffered saline (pH 7.4) con-
taining 4.0 mM ethylenediaminetetraacetic acid, and
the radioactivity was quantified using a Bioscan IAR-2000
thin-layer chromatography imaging scanner (Washington,
DC). Free 64Cu2+ moved to the solvent front (Rf = 0.9-1.0),
and the nanoparticles remained at the original spot
(Rf = 0.0). The labeling efficiency was > 95%.Transmission electron microscopy (TEM)
The tissue uptake of PEG-HAuNS was studied by TEM.
Briefly, sections of liver tissue from a control mouse and
a male mouse at 14-day time point were fixed with a so-
lution containing 3% glutaraldehyde plus 2% paraformal-
dehyde in 1.0 M cacodylate buffer (pH 7.3) for 1 h.
After fixation, the samples were washed and treated
with 0.1% Millipore-filtered (Billerica, MA), cacodylate-
buffered tannic acid, post-fixed with 1% buffered os-
mium tetroxide for 30 min, and stained en bloc with
1% Millipore-filtered uranyl acetate. The samples were
dehydrated in increasing concentrations of ethanol, in-
filtrated, and embedded in Ladd-112 medium. The
samples were polymerized in an oven at 70°C for 2 days.
Ultrathin sections were cut in a Leica Ultracut micro-
tome (Deerfield, IL), stained with uranyl acetate and
lead citrate in a Leica EM stainer, and examined in a
JEM 1010 transmission electron microscope (JEOL
USA, Inc.) at an accelerating voltage of 80 KV. Digital
images were obtained using the AMT Imaging System
(Advanced Microscopy Techniques Corp, Danvers, MA).Cytotoxicity
Cytotoxicity was measured using the MTT assay accord-
ing to the manufacturer’s suggested procedures. LLC-
PK1 and HepG2 cells were exposed to PEG-HAuNS at
various concentrations for 4, 24, and 48 h. The data are
expressed as percentage of survival cells and are re-
ported as the means of triplicate measurements in a sin-
gle experiment.
Complement activation
Platelet-poor plasma was prepared by centrifugation of
freshly drawn whole human blood for 10 min at 2,500 g
and was used fresh. Complement activation experiments
were performed as described previously (http://ncl.can-
cer.gov/NCL_Method_ITA-5.pdf ). Briefly, equal volumes
(10 μL) of test samples (PEG-HAuNS at final concentra-
tion of 1 mg/mL, cobra venom factor at concentration
of 50 U as positive control, or PBS as negative control),
freshly prepared plasma, and veronal-buffer were mixed
together and incubated at 37°C for 60 min. The reaction
was stopped by the addition of 4 × NuPAGE sample buf-
fer (Invitrogen, Carlsbad, CA). After heating for 5 min at
90°C, 30 μL of the sample were resolved on 10% Trisglycine
gel. For Western blot analysis, proteins separated by 2-
dimensional polyacrylamide gel electrophoresis were trans-
ferred onto a Westran S nylon (Whatman Inc., Florham
Park, NJ) membrane and probed with goat polyclonal
antibodies specific to C3 component of complement
(Calbiochem, San Diego, CA).
Platelet aggregation
To study the nanoparticles’ effects on platelet aggregation,
whole human blood was centrifuged 8 min at 200 g to ob-
tain platelet-rich plasma, which was then treated with
PEG-HAuNS (0.008, 0.04, 0.2, and 1.0 mg/mL) or collagen
(positive control; Helena Laboratories, Beaumont, TX) for
15 min at 37°C. To investigate whether PEG-HAuNS
can interfere with collagen-induced platelet aggrega-
tion, platelet-rich plasma was also treated with the mix-
ture of collagen and PEG-HAuNS under the same
conditions. A single-platelet count was then conducted
using a Z2 counter and size analyzer (Beckman Coulter,
Inc.). A decrease in the single-platelet count occurring
due to the platelet aggregation was used to calculate
percentage aggregation. A detailed protocol is available
at http://ncl.cancer.gov/NCL Method ITA-2.pdf.
Pharmacokinetics and biodistribution
All animal studies were carried out at MD Anderson
Cancer Center (MDACC) under Institutional Animal
Care and Use Committee-approved protocols. All animal
cages were sanitized on a regular schedule. No known
contaminants were present in the bedding which could
interfere and affect the results of the study. Diet was a
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source was the public supply given ad libitum. Mice were
killed by CO2 exposure at the end of the each study.
For the pharmacokinetic study, 8 healthy female Swiss
mice (22–25 g; Charles River Laboratories, Wilmington,
MA) were each injected intravenously with 0.125 mL of
64Cu-labeled PEG-HAuNS (activity: 20 μCi; 6.25 mg/kg
of 50 OD PEG-HAuNS). At predetermined intervals
(0 to ~24 h), blood samples (10 μL) were taken from the
tail vein, and the radioactivity of each sample was mea-
sured with a gamma counter (Packard, Downers Grove,
IL). The percentage of the injected dose per gram of blood
(%ID/g) was calculated. The blood pharmacokinetic pa-
rameters for the radiotracer were analyzed using a non-
compartmental model with WinNonlin 5.0.1 software
(Pharsight, Palo Alto, CA).
For the biodistribution study, human ovarian cancer tu-
mors were generated by subcutaneous injection of Hey
cells (5.0 × 106 cells/mouse, n = 6) in female nu/nu nude
mice (Charles River Laboratories). When the average
tumor size reached 6–8 mm in average diameter, the mice
were injected subcutaneously with 0.125 mL 64Cu-labeled
PEG-HAuNS (activity: 20 μCi; 6.25 mg/kg of 50 OD
PEG-HAuNS). The mice were killed at 24 h after injec-
tion. Various tissues, including tumors, were collected and
weighed. The radioactivity of each sample was measured
with a Cobra gamma counter (Packard Instruments,
Downers Grove, IL). Uptake of nanoparticles in various
tissues was calculated as %ID/g.Antitumor activity
The antitumor activity of PEG-HAuNS at different
doses was investigated in female nude mice (Charles
River Laboratories) bearing human ovarian tumors. The
tumors were generated by subcutaneous injection of
Hey cells (5 × 106 cells/mouse). The diameter of tumors
was measured by a vernier caliper, and the tumor volume
was calculated according to the following equation:
volume = (tumor length) × (tumor width)2/2. When the
tumor volume reached ~300 mm3, the mice were divided
into 4 groups consisting of 7 or 8 mice/group. Mice in
groups 1 to 3 were injected intravenously with a single
dose of PEG-HAuNS (5 mL/kg of 25, 50, or 100 OD
nanoparticles, corresponding to 3.13 mg/kg, 6.25 mg/kg,
or 13.5 mg/kg, respectively). The mice in group 4, as
controls, were injected intravenously with a single dose
of saline (5 mL/kg). Tumors in all of the groups were
irradiated with an NIR laser (2.5 W/cm2 for 3 min) at
24 h after drug injection. The tumors were measured as
described before. At the end of the experiment (tumors
reached >1,500 mm3 or 10 days after initial injection,
whichever came first), the mice were killed and the tu-
mors removed and weighed.Human ovarian A2780 tumors were generated by sub-
cutaneous injection of the cells (8.0 × 106 cells/mouse).
When tumor volume reached ~500 mm3, mice were di-
vided into two groups. Mice in group 1 (n = 6) were
injected intravenously with saline (5.0 mL/kg) and mice
in group 2 (n = 7) were injected with PEG-HAuNS
(5.0 mL/kg of 50 OD; 6.25 mg/kg). Mice in both groups
were irradiated with NIR laser (Diomed 15 plus, UK)
above the skin surface at 24 h after injection at a power
density of 2.5 W/cm2 for 3 min). The tumor dimensions
were measured with a caliper, and the tumor volume
was calculated according to the equation: Volume =
(Tumor Length) × (Tumor Width)2/2. At the end of the
experiment (tumors reached > 2000 mm3 or 22 days
after initial injection, whichever came first), mice were
killed by CO2 overexposure and tumors were removed
and weighed.
Acute and chronic toxicity
A total of 24 male and 24 female 8 weeks CD1 mice
(Charles River Laboratories) were assigned to 4 groups
(6 mice/sex/group). Two groups were injected intraven-
ously with PEG-HAuNS (treated) at a dose of 12.5 mg/kg
(accumulated dose: 125 mg/kg) and 2 were injected with
saline (controls), for a total of 10 injections, administered
daily for 5 injections per week over a 2-week period. At 14
and 90 days from the first injection, 12 mice (6 male, 6 fe-
male) were killed. The following tissues were collected at
necropsy for histological examination: liver, gall bladder,
kidneys, lungs, spleen, skeletal muscle, heart, aorta, ad-
renal glands, brain, eyes, lacrimal glands, pituitary gland,
sciatic nerve, spinal cord, pancreas, stomach, duodenum,
jejunum, ileum, cecum, colon, rectum, mesenteric lymph
node, salivary glands, mandibular lymph node, thymus,
larynx/pharynx with tongue, thyroid gland, parathyroid
glands, trachea, esophagus, skin, mammary glands (fe-
males only), urinary bladder, female reproductive organs
(ovaries, uterus, cervix), male reproductive organs (testes,
epididymis, prostate, seminal vessicles), femur with knee
joint, sternum, sternal bone marrow, and injection site
(tail vein). At the time of necropsy, cardiac blood was
collected for hematologic and clinical chemistry ana-
lysis, and any gross observations were noted. Selected
organs were weighed at the time of necropsy (liver,
spleen, kidneys), and relative organ weights were calcu-
lated on the basis of the terminal body weights. All tis-
sues were fixed in 10% neutral buffered formalin,
processed into paraffin-embedded blocks, and cut into
5-micron sections for histologic examination by a
board-certified veterinary pathologist.
To investigate the elimination of PEG-HAuNS in mice,
the Au content of liver, spleen, kidney, and muscle sam-
ples of 6 CD1 mice (3 male, 3 female) killed at day 14 and
day 90 was measured using neutron activation analysis at
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(Columbia, MO). Tissue samples were prepared by weigh-
ing the as-received samples into precleaned, high-density
polyethylene irradiation vials and lyophilizing the tissue to
constant dry weight. The samples were then loaded in
polyethylene transfer “rabbits” in sets of nine and were ir-
radiated for 90 s in a thermal flux density of approxi-
mately 5 × 1013 n cm−2 s−1. The samples were then
allowed to decay for 24 to 48 h and counted in real time
on a high-purity germanium detector for 3600 s at a
sample-to-detector distance of approximately 5 cm.
The mass of gold in a sample was quantified by meas-
uring the 411.8 KeV gamma ray from the β− decay of
198Au (t1/2 = 2.7 days). Six geometrically equivalent
comparator standards, prepared by pipetting approxi-
mately 0.1 (n = 3) and 0.01 (n = 3) mg of gold from a
(10.0 ± 0.5) μg/mL certified standard solution (High-
Purity Standards) on paper pulp in the polyethylene irradi-
ation vials, were used with each sample set.
Statistics
Mean differences in tumor size at the 10th day of treat-
ment between the 4 treatment groups of mice with Hey
tumors were analyzed by analysis of variance, with p <
0.05 considered to be statistically significant. Difference
on tissue concentration between day-14 and day-90 after
the first injection was analyzed using student’s t-test
(paired, two-tail test).
Additional file
Additional file 1: Table S1. Group means for terminal body weights
(TBW) for both the 14-day and 90-day sacrifices and the calculated percent
of control for each sacrifice date. Table S2. Group means of organ weight
relative to body weight and percent of control for both sacrifice dates and
sexes. Table S3. Group means for both sacrifice dates and both sexes for
hematology. Table S4. Summary of incidences and average group grades
for all microscopic observations. Figure S1. Cell viability as a function of
PEG-HAuNS concentration. LLC-PK1 (A) and HepG2 (B) cells were treated
with PEG-HAuNS for 4, 24, and 48 hr. The viability of cells was determined
using the MTT assay. Figure S2. Antitumor activity of PEG-HAuNS against
A2780 tumor in nude mice. A: A2780 tumor growth curves in mice treated
with saline (n = 6) and with PEG-HAuNS (n = 7). All tumors in both groups
received NIR laser illumination from the tumor’s surface (2.5 W/cm2, for 3
min) at 24 h after intravenous injection of PEG-HAuNS (single, 6.25 mg/kg).
B: Average tumor weight in saline- and PEG-HAuNS-treated groups on day
21 after NIR laser illumination. Figure S3. Spleen with pigment. The 14-day
pigment deposition is much greater than what is observed at 90 days.
At 14 days, the pigment deposits were smaller and distributed diffusely
throughout the spleen. At 90 days, the deposits were larger and fewer,
and focal and random throughout the spleen. Magnification, ×400.
Competing interest
The authors have no potential competing interest to disclose.
Authors’ contributions
JY carried out all studies and drafted the manuscript. JZ participated in data
analysis and manuscript preparation. MZ participated in biodistribution study.
YL participated in the synthesis of PEG-HAuNS. JDR carried out quantitative
analysis of tissue concentration of Au. DL carried out pharmacokinetic analysis.CVP designed in vivo toxicity study, carried out tissue histopathological analysis,
and drafted the manuscript. CL designed the work and drafted the manuscript.
All authors read and approved the final manuscript.Acknowledgment
We thank Luanne Jorewicz for editing the article. The blood compatibility
assays (complement activation and platelet aggregation) were performed at
Nanotechnology Characterization Lab (NCL), National Cancer Institute. This
work was supported in part by the National Cancer Institute (U54CA151668),
the John S. Dunn Foundation and the National Nature Science Foundation
of China (81373348 and 81001411). SEM and TEM studies were performed at
the High Resolution Transmission Electron Microscopy Core of MD Anderson
Cancer Center.
Author details
1College of Pharmaceutical Sciences, Zhejiang University, Yuhangtang Road
388, Hangzhou 310058, People’s Republic of China. 2Department of Cancer
Systems Imaging, Unit 59, The University of Texas MD Anderson Cancer
Center, Houston, TX 77030, USA. 3Department of Chemistry, University of
Missouri-Columbia, Columbia, MO 65211, USA. 4Department of
Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas
Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
5Department of Veterinary Medicine and Surgery, The University of Texas MD
Anderson Cancer Center, Houston 77030, TX, USA.
Received: 27 December 2013 Accepted: 3 May 2014
Published: 30 May 2014References
1. Caruthers SD, Wickline SA, Lanza GM: Nanotechnological applications in
medicine. Curr Opin Biotechnol 2007, 18:26–30.
2. Li C: A targeted approach to cancer imaging and therapy. Nat Mater
2014, 13:110–115.
3. Guzman KAD, Taylor MR, Banfield JF: Environmental risks of
nanotechnology: national nanotechnology initiative funding, 2000–2004.
Environ Sci Technol 2006, 40:1401–1407.
4. Borm PJA, Muller-Schulte D: Nanoparticles in drug delivery and environmental
exposure: same size, same risks? Nanomedicine 2006, 1:235–249.
5. Carrero-Sanchez JC, Elias AL, Mancilla R, Arrellin G, Terrones H, Laclette JP,
Terrones M: Biocompatibility and toxicological studies of carbon
nanotubes doped with nitrogen. Nano Lett 2006, 6:1609–1616.
6. Fiorito S, Serafino A, Andreola F, Togna A, Togna G: Toxicity and
biocompatibility of carbon nanoparticles. J Nanosci Nanotechnol 2006,
6:591–599.
7. Federici G, Shaw BJ, Handy RD: Toxicity of titanium dioxide nanoparticles
to rainbow trout (oncorhynchus mykiss): gill injury, oxidative stress, and
other physiological effects. Aquat Toxicol 2007, 84:415–430.
8. Chen J, Dong X, Zhao J, Tang G: In vivo acute toxicity of titanium dioxide
nanoparticles to mice after intraperitioneal injection. J Appl Toxicol 2009,
29:330–337.
9. Gurr JR, Wang ASS, Chen CH, Jan KY: Ultrafine titanium dioxide particles in
the absence of photoactivation can induce oxidative damage to human
bronchial epithelial cells. Toxicology 2005, 213:66–73.
10. Pissuwan D, Valenzuela SM, Cortie MB: Therapeutic possibilities of
plasmonically heated gold nanoparticles. Trends Biotechnol 2006, 24:62–67.
11. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, Yang L, Young
AN, Wang MD, Nie S: In vivo tumor targeting and spectroscopic detection
with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 2008,
26:83–90.
12. Costi R, Saunders AE, Elmalem E, Salant A, Banin U: Visible light-induced
charge retention and photocatalysis with hybrid CdSe-Au nanodumbbells.
Nano Lett 2008, 8:637–641.
13. Kerman K, Kraatz HB: Electrochemical detection of kinase-catalyzed
thiophosphorylation using gold nanoparticles. Chem Commun 2007,
21:5019–5021.
14. Poon L, Zandberg W, Hsiao D, Erno Z, Sen D, Gates BD, Branda NR:
Photothermal release of single-stranded DNA from the surface of gold
nanoparticles through controlled denaturating and Au-S bond breaking.
ACS Nano 2010, 4:6395–6403.
You et al. Particle and Fibre Toxicology 2014, 11:26 Page 14 of 14
http://www.particleandfibretoxicology.com/content/11/1/2615. Nusz GJ, Curry AC, Marinakos SM, Wax A, Chilkoti A: Rational selection of
gold nanorod geometry for label-free plasmonic biosensors. ACS Nano
2009, 3:795–806.
16. Ghosh PS, Kim CK, Han G, Forbes NS, Rotello VM: Efficient gene delivery
vectors by tuning the surface charge density of amino acid-functionalized
gold nanoparticles. ACS Nano 2008, 2:2213–2218.
17. Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ,
Plumb JA, Graham D, Wheate NJ: Gold nanoparticles for the improved
anticancer drug delivery of the active component of oxaliplatin.
J Am Chem Soc 2010, 132:4678–4684.
18. Elbakry A, Zaky A, Liebkl R, Rachel R, Goepferich A, Breunig M: Layer-by-layer
assembled gold nanoparticles for siRNA delivery. Nano Lett 2009,
9:2059–2064.
19. Merchant B: Gold, the noble metal and the paradoxes of its toxicology.
Biologicals 1998, 26:49–59.
20. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD: Gold nanoparticles
are taken up by human cells but do not cause acute cytotoxicity.
Small 2005, 1:325–327.
21. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M:
Biocompatibility of gold nanoparticles and their endocytotic fate inside
the cellular compartment: a microscopic overview. Langmuir 2005,
21:10644–10654.
22. Goodman CM, McCusker CD, Yilmaz T, Rotello VM: Toxicity of gold
nanoparticles functionalized with cationic and anionic side chains.
Bioconjugate Chem 2004, 15:897–900.
23. Pernodet N, Fang XH, Sun Y, Bakhtina A, Ramakrishnan A, Sokolov J, Ulman
A, Rafailovich M: Adverse effects of citrate/gold nanoparticles on human
dermal fibroblasts. Small 2006, 2:766–773.
24. Chithrani BD, Chan WC: Elucidating the mechanism of cellular uptake and
removal of protein-coated gold nanoparticles of different sizes and
shapes. Nano Lett 2007, 7:1542–1550.
25. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, Schmid G, Brandau W,
Jahnen-Dechent W: Size-dependent cytotoxicity of gold nanoparticles.
Small 2007, 3:1941–1949.
26. Alkilany AM, Murphy CJ: Toxicity and cellular uptake of gold
nanoparticles: what we have learned so far? J Nanopart Res 2010,
12:2313–2333.
27. Lee S, Chon H, Lee M, Choo J, Shin SY, Lee YH, Rhyu IJ, Son SW, Oh CH:
Surface-enhanced Raman scattering imaging of HER2 cancer markers
overexpressed in single MCF7 cells using antibody conjugated hollow
gold nanospheres. Biosens Bioelectron 2009, 24:2260–2263.
28. Lu W, Huang Q, Geng KB, Wen XX, Zhou M, Guzatov D, Brecht P, Su R,
Oraevsky A, Wang LV, Li C: Photoacoustic imaging of living mouse brain
vasculature using hollow gold nanospheres. Biomaterials 2010,
31:2617–2626.
29. Melancon MP, Lu W, Yang Z, Zhang R, Cheng Z, Elliot AM, Stafford J, Olson
T, Zhang JZ, Li C: In vitro and in vivo targeting of hollow gold nanoshells
directed at epidermal growth factor receptor for photothermal ablation
therapy. Mol Cancer Ther 2008, 7:1730–1739.
30. Melancon MP, Zhou M, Li C: Cancer theranostics with near-infrared
light-activatable multimodal nanoparticles. Acc Chem Res 2011, 44:947–956.
31. Kumar R, Maitra AN, Patanjali PK, Sharma P: Hollow gold nanoparticles
encapsulating horseradish peroxidase. Biomaterials 2005, 26:6743–6753.
32. Lu W, Zhang G, Zhang R, Flores LG 2nd, Huang Q, Gelovani JG, Li C: Tumor
site-specific silencing of NF-kappaB p65 by targeted hollow gold
nanosphere-mediated photothermal transfection. Cancer Res 2010,
70:3177–3188.
33. You J, Shao R, Wei X, Gupta S, Li C: Near-infrared light triggers release of
paclitaxel from biodegradable microspheres: photothermal effect and
enhanced antitumor activity. Small 2010, 6:1022–1031.
34. You J, Zhang G, Li C: Exceptionally high payload of doxorubicin in hollow
gold nanospheres for near-infrared light-triggered drug release.
ACS Nano 2010, 4:1033–1041.
35. Wu G, Mikhailovsky A, Khant HA, Fu C, Chiu W, Zasadzinski JA: Remotely
triggered liposome release by near-infrared light absorption via hollow
gold nanoshells. J Am Chem Soc 2008, 130:8175–8177.
36. Patra HK, Banerjee S, Chaudhuri U, Lahiri P, Dasgupta AK: Cell selective
response to gold nanoparticles. Nanomedicine 2007, 3:111–119.
37. Lankveld DP, Rayavarapu RG, Krystek P, Oomen AG, Verharen HW, van
Leeuwen TG, De Jong WH, Manohar S: Blood clearance and tissuedistribution of PEGylated and non-PEGylated gold nanorods after
intravenous administration in rats. Nanomedicine (Lond) 2011, 6:339–349.
38. Akiyama Y, Mori T, Katayama Y, Niidome T: The effects of PEG grafting
level and injection dose on gold nanorod biodistribution in the
tumor-bearing mice. J Control Release 2009, 139:81–84.
39. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T,
Katayama Y, Niidome Y: PEG-modified gold nanorods with a stealth
character for in vivo applications. J Control Release 2006, 114:343–347.
40. Zhang G, Yang Z, Lu W, Zhang R, Huang Q, Tian M, Li L, Liang D, Li C:
Influence of anchoring ligands and particle size on the colloidal stability
and in vivo biodistribution of polyethylene glycol-coated gold
nanoparticles in tumor-xenografted mice. Biomaterials 2009, 30:1928–1936.
41. Elwell M, Mahler J: Heart, blood vessels, and lymphatics. In Pathology of
the Mouse Reference and Atlas. Edited by Maronpot R. Vienna, IL: Cache River
Press; 1999:361–380.
doi:10.1186/1743-8977-11-26
Cite this article as: You et al.: Pharmacokinetics, clearance, and biosafety
of polyethylene glycol-coated hollow gold nanospheres. Particle and
Fibre Toxicology 2014 11:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
